Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Keros Therapeutics, Inc. (KROS) vs Veraxa Biotech AG (VRXA)

Keros Therapeutics, Inc. and Veraxa Biotech AG are both Biotechnology companies. Keros Therapeutics, Inc. and Veraxa Biotech AG are of similar size ($229.0M and $217.0M).

Valuation

Metric KROS VRXA Biotechnology median
P/E n/m — 7.88
P/S 6.97 — 11.47
P/B 0.88 — 2.52
Price to free cash flow n/m — 21.16
EV/EBITDA 0.26 — 0.74
EV/Sales (0.79) — 10.73
Earnings yield (31.68%) — (28.84%)
Free cash flow yield (20.97%) — (23.03%)

Profitability

Metric KROS VRXA Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity (17.16%) — (57.72%)
Return on assets (15.92%) — (49.22%)
Return on invested capital (1,345.30%) — 0.00%

Growth

Metric KROS VRXA Biotechnology median
Revenue growth (TTM) (84.55%) — 5.64%
EPS growth (last fiscal year) 146.00% — —
Revenue growth, 5-year CAGR 89.45% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric KROS VRXA Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 21.96 — 4.73
Net debt to EBITDA (4.16) — 0.96

Dividend

Metric KROS VRXA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric KROS VRXA Biotechnology median
Market cap 229.00m 217.00m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack